Program
Esketamine
Also written as “Esketamine 84 mg”, “Esketamine 56 mg” and “AM-101”.
Its studies are mostly in Depressive Disorder, Treatment-Resistant · Depressive Disorder, Major · Tinnitus · Depression · Substance-Related Disorders, led by 3 companies.
Drug pageEsketamine: every studyAll 243 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 412 open or running | phase 4since Oct 21, 2020 | Jul 11, 2012 | Dec 27, 2028phase 3 · NCT07716098 |
| Celon Pharmaits history only | 30 open or running | phase 2since May 21, 2019 | Jan 8, 2018 | none ahead |
| Chengdu Brilliant Pharmaceutical | 10 open or running | phase 3since Sep 21, 2023 | Sep 21, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chengdu Brilliant Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 21, 2023First study: phase 3 study in LaparoscopyFirst studyNCT06092684 · 358 enrolled · China
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Memantinerule | AbbVie | phase 4 | 29 |
Studies
The one study Chengdu Brilliant Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06092684Laparoscopy · China | 3 | Completed | Mar 19, 2024 | 358 |
How it is read
Names in the registry
- “Esketamine”, 30 entries
- “Esketamine 84 mg”, 8 entries
- “Esketamine 56 mg”, 7 entries
- “AM-101”, 5 entries
- “Esketamine 28 mg”, 3 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Treatment-Resistant, 12 studies
- Depressive Disorder, Major, 10 studies
- Tinnitus, 6 studies
- Depression, 3 studies
- Substance-Related Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.